Visseren FLJ - Search Results

1

Improving 10-year cardiovascular risk prediction in apparently healthy people: flexible addition of risk modifiers on top of SCORE2.

Hageman SHJ, Petitjaen C, Pennells L, Kaptoge S, Pajouheshnia R, Tillmann T, Blaha MJ, McClelland RL, Matsushita K, Nambi V, Klungel OH, Souverein PC, van der Schouw YT, Verschuren WMM, Lehmann N, Erbel R, Jöckel KH, Di Angelantonio E, Visseren FLJ, Dorresteijn JAN. Hageman SHJ, et al. Among authors: visseren flj. Eur J Prev Cardiol. 2023 Oct 26;30(15):1705-1714. doi: 10.1093/eurjpc/zwad187. Eur J Prev Cardiol. 2023. PMID: 37264679 Free PMC article.

2

Renal function as a risk indicator for cardiovascular events in 3216 patients with manifest arterial disease.

Bax L, Algra A, Mali WP, Edlinger M, Beutler JJ, van der Graaf Y; SMART study group. Bax L, et al. Atherosclerosis. 2008 Sep;200(1):184-90. doi: 10.1016/j.atherosclerosis.2007.12.006. Epub 2008 Feb 1. Atherosclerosis. 2008. PMID: 18241872

3

Pharmacogenomic insights into treatment and management of statin-induced myopathy.

Peters BJ, Klungel OH, Visseren FL, de Boer A, Maitland-van der Zee AH. Peters BJ, et al. Genome Med. 2009 Dec 29;1(12):120. doi: 10.1186/gm120. Genome Med. 2009. PMID: 20090898 Free PMC article.

4

A prediction model for left ventricular mass in patients at high cardiovascular risk.

Meijs MF, Vergouwe Y, Cramer MJ, Vonken EJ, Velthuis BK, Verton DJ, van der Graaf Y, Visseren FL, Mali WP, Doevendans PA, Bots ML; SMART study group. Meijs MF, et al. Eur J Cardiovasc Prev Rehabil. 2010 Dec;17(6):621-7. doi: 10.1097/HJR.0b013e328332d4bc. Eur J Cardiovasc Prev Rehabil. 2010. PMID: 20814310

5

[Obesity-related hypertension].

Dorresteijn JA, Visseren FL, van den Meiracker AH, Spiering W. Dorresteijn JA, et al. Ned Tijdschr Geneeskd. 2011;154:A1945. Ned Tijdschr Geneeskd. 2011. PMID: 21418695 Review. Dutch.

6

Relation between thyroid-stimulating hormone and the occurrence of cardiovascular events and mortality in patients with manifest vascular diseases.

Westerink J, van der Graaf Y, Faber DR, Spiering W, Visseren FL; SMART study group. Westerink J, et al. Eur J Prev Cardiol. 2012 Aug;19(4):864-73. doi: 10.1177/1741826711416045. Epub 2011 Jul 1. Eur J Prev Cardiol. 2012. PMID: 21724680

7

Mechanisms linking obesity to hypertension.

Dorresteijn JA, Visseren FL, Spiering W. Dorresteijn JA, et al. Obes Rev. 2012 Jan;13(1):17-26. doi: 10.1111/j.1467-789X.2011.00914.x. Epub 2011 Aug 10. Obes Rev. 2012. PMID: 21831233 Review.

8

Prediction model with metabolic syndrome to predict recurrent vascular events in patients with clinically manifest vascular diseases.

Wassink AM, van der Graaf Y, Janssen KJ, Cook NR, Visseren FL; SMART Study Group. Wassink AM, et al. Eur J Prev Cardiol. 2012 Dec;19(6):1486-95. doi: 10.1177/1741826711426636. Epub 2011 Oct 18. Eur J Prev Cardiol. 2012. PMID: 22008749

9

The combined use of aspirin, a statin, and blood pressure-lowering agents (polypill components) in clinical practice in patients with vascular diseases or type 2 diabetes mellitus.

Lafeber M, Grobbee DE, Spiering W, van der Graaf Y, Bots ML, Visseren FL; SMART Study Group. Lafeber M, et al. Eur J Prev Cardiol. 2013 Oct;20(5):771-8. doi: 10.1177/2047487312449587. Epub 2012 May 30. Eur J Prev Cardiol. 2013. PMID: 22649123

10

The evening versus morning polypill utilization study: the TEMPUS rationale and design.

Lafeber M, Grobbee DE, Bots ML, Thom S, Webster R, Rodgers A, Visseren FL, Spiering W. Lafeber M, et al. Eur J Prev Cardiol. 2014 Apr;21(4):425-33. doi: 10.1177/2047487313476961. Epub 2013 Feb 4. Eur J Prev Cardiol. 2014. PMID: 23382539 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

469 results

Search Page